The MRNA stock price fluctuated between $329.26 and $361.76 throughout the trading session with the volume trading being 23M shares, which represented a positive variation when compared to the three months average volume of 13M shares.
The share price of Moderna, Inc. (NasdaqGS:MRNA) dipped -3.72% to close Monday’s market session at $335.87, lower as compared to yesterday’s close which brings the market valuation of the company to $134.86B.
The 52-week high for the Moderna, Inc.’s shares is $361.76. That puts it -7.16% from that peak but still a 336.53% gain since the share price dropped to a 52-week low of $54.21, while the S&P 500’s share price change was of 36.19%.
The company currently has a 225.11 P/E ratio and a price target of $184.92.
What does the trading volume tell us about the MRNA stock?
During the last trading session, Moderna, Inc. (NasdaqGS:MRNA) has seen growth in its daily volume. The daily volume was of 13M, while in the last 10 days the average was 45.12M and last three months – 12.55M.
The increasing interest in the MRNA stock from the investors is helping to drive the stock price up.
Growing short interest
The Moderna, Inc.’s shares are seeing an increasing short interest compared to the previous month. As of today, there are 12.46M shares being shorted which translates into 1.3 of a short ratio for MRNA, while in the previous month the shorted shares were 11.83M.
Moderna, Inc. (NasdaqGS:MRNA) financials
With a market cap of 134.86B, Moderna, Inc. holds a total cash of $7.74B that translates into $19.26 per share, while the total debt is of $279M.
The company has seen a decrease in the revenue with a year-over-year quarterly revenue growth percentage of 24,112.50%. The current revenue is of $2.73B that is $6.95 per share.
This is a an exceptional sign for the future.